Zobrazit více v PubMed
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019;139:e56–28.
PubMed
Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34:2746–51.
PubMed
PMC
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67.
PubMed
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.
PubMed
Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA 2021;326:2395–404.
PubMed
PMC
Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006;32:77–85.
PubMed
Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013;128:2192–201.
PubMed
Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022;145:242–55.
PubMed
PMC
Little D, Chai-Adisaksopha C, Hillis C, Witt DM, Monreal M, Crowther MA, et al. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. Thromb Res 2019;175:102–9.
PubMed
Karim N, Ho SY, Nicol E, Li W, Zemrak F, Markides V, et al. The left atrial appendage in humans: structure, physiology, and pathogenesis. Europace 2020;22:5–18.
PubMed
Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017;70:2964–75.
PubMed
Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. 4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol 2022;79:1–14.
PubMed
Turagam MK, Osmancik P, Neuzil P, Dukkipati SR, Reddy VY. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol 2020;76:2795–7.
PubMed
Turagam MK, Kawamura I, Neuzil P, Nair D, Doshi S, Valderrabano M, et al. Severity of ischemic stroke after left atrial appendage closure vs nonwarfarin oral anticoagulants. JACC Clin Electrophysiol 2023. doi:10.1016/j.jacep.2023.10.012. Epub ahead of print.
PubMed
DOI
Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention 2016;11:1170–9.
PubMed
Hildick-Smith D, Landmesser U, Camm AJ, Diener HC, Paul V, Schmidt B, et al. Left atrial appendage occlusion with the Amplatzer Amulet device: full results of the prospective global observational study. Eur Heart J 2020;41:2894–901.
PubMed
PMC
Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 2017;14:1302–8.
PubMed
Freeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, et al. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol 2020;75:1503–18.
PubMed
PMC
Price MJ, Slotwiner D, Du C, Freeman JV, Turi Z, Rammohan C, et al. Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States. JACC Cardiovasc Interv 2022;15:741–50.
PubMed
PMC
Doshi SK, Kar S, Sadhu A, Horton R, Osorio J, Ellis C, et al. Two-year outcomes with a next-generation left atrial appendage device: final results of the PINNACLE FLX trial. J Am Heart Assoc 2023;12:e026295.
PubMed
PMC
Waranugraha Y, Lin LY, Tsai CT. Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: a systematic review and meta-analysis study. Trends Cardiovasc Med 2023. doi:10.1016/j.tcm.2023.02.002. Epub ahead of print.
PubMed
DOI
Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021;384:2081–91.
PubMed
Bayer . A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke. 2022. https://classic.clinicaltrials.gov/show/NCT05643573 (8 February 2024, date last accessed).
Anthos Therapeutics Inc., The TIMI Study Group, Laboratory Corporation of America . Safety and tolerability of abelacimab (MAA868) vs. rivaroxaban in patients with atrial fibrillation. 2021. https://classic.clinicaltrials.gov/show/NCT04755283 (8 February 2024, date last accessed).
Anthos Therapeutics Inc . Study to evaLuate the effIcacy and aafety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC-TIMI 76). 2022. https://classic.clinicaltrials.gov/show/NCT05712200 (8 February 2024, date last accessed).
Janssen Research Development LLC, Bristol-Myers Squibb . A study of Milvexian versus apixaban in participants with atrial fibrillation. 2023. https://classic.clinicaltrials.gov/show/NCT05757869 (8 February 2024, date last accessed).
Boston Scientific Corporation . Assessment of the WATCHMAN™ device in patients unsuitable for oral anticoagulation. 2017. https://classic.clinicaltrials.gov/show/NCT02928497 (8 February 2024, date last accessed).
Charite University Berlin Germany, Deutsches Zentrum für Herz-Kreislauf-Forschung, Atrial Fibrillation Network, Stiftung Institut fuer Herzinfarktforschung . Left atrial appendage CLOSURE in patients with atrial fibrillation compared to medical therapy. 2018. https://classic.clinicaltrials.gov/show/NCT03463317 (8 February 2024, date last accessed).
Karolinska Institutet, Abbott Medical Devices . Prevention of stroke by left atrial appendage closure in atrial fibrillation patients after intracerebral hemorrhage. 2017. https://classic.clinicaltrials.gov/show/NCT02830152 (8 February 2024, date last accessed).
Jena University Hospital . Comparison of LAA-closure vs oral anticoagulation in patients with NVAF and status post intracranial bleeding. 2020. https://classic.clinicaltrials.gov/show/NCT04298723 (8 February 2024, date last accessed).
Huijboom M, Maarse M, Aarnink E, van Dijk V, Swaans M, van der Heijden J, et al. COMPARE LAAO: rationale and design of the randomized controlled trial “Comparing effectiveness and safety of left atrial appendage occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy”. Am Heart J 2022;250:45–56.
PubMed
R&D Cardiologie, Research ZTNOfH, Development . Left atrial appendage occlusion for AF patients unable to use oral anticoagulation therapy. 2021. https://classic.clinicaltrials.gov/show/NCT04676880 (8 February 2024, date last accessed).
Eitel I. Left atrial appendage closure in patients with non-valvular atrial fibrillation and end-stage chronic KIDNEY disease. 2022. https://classic.clinicaltrials.gov/show/NCT05204212 (8 February 2024, date last accessed).
Wazni OM, Boersma L, Healey JS, Mansour M, Tondo C, Phillips K, et al. Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: rationale and design of the OPTION randomized trial. Am Heart J 2022;251:35–42.
PubMed
Boston Scientific Corporation . Comparison of anticoagulation with left atrial appendage closure after AF ablation. 2019. https://classic.clinicaltrials.gov/show/NCT03795298 (8 February 2024, last date accessed).
Kar S, Doshi SK, Alkhouli M, Camm AJ, Coylewright M, Gibson MC, et al. Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation. Am Heart J 2023;264:123–32.
PubMed
Abbott Medical Devices . Amplatzer Amulet LAAO vs. NOAC. 2020. https://classic.clinicaltrials.gov/show/NCT04226547 (8 February 2024, date last accessed).
University of Aarhus Aarhus University Hospital Aalborg University Hospital Odense University Hospital Sahlgrenska University Hospital Sweden Karolinska University Hospital, et al. Left atrial appendage occlusion versus novel oral anticoagulation for stroke prevention in atrial fibrillation. 2019. https://classic.clinicaltrials.gov/show/NCT03642509 (8 February 2024, date last accessed).
Korsholm K, Damgaard D, Valentin JB, Packer EJS, Odenstedt J, Sinisalo J, et al. Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial. Am Heart J 2022;243:28–38.
PubMed
Nielsen-Kudsk JE, Johnsen SP, Wester P, Damgaard D, Airaksinen J, Lund J, et al. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention 2017;13:371–8.
PubMed
Nielsen-Kudsk JE, Korsholm K, Damgaard D, Valentin JB, Diener HC, Camm AJ, et al. Clinical outcomes associated with left atrial appendage occlusion versus direct oral anticoagulation in atrial fibrillation. JACC Cardiovasc Interv 2021;14:69–78.
PubMed
Lip GYH, Proietti M, Potpara T, Mansour M, Savelieva I, Tse HF, et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace 2023;25:euad226.
PubMed
PMC
Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. Adherence to the ‘atrial fibrillation better care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-A systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022;122:406–14.
PubMed
Patel SM, Palazzolo MG, Murphy SA, Antman EM, Braunwald E, Lanz HJ, et al. Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. Europace 2022;24:1730–8.
PubMed
Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management with the ABC (atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc 2020;9:e014932.
PubMed
PMC
Shrestha B, Poudel B, Poudel D, Diaz Fraga J. National yearly trend of utilization and procedural complication of the watchman device in the United States. Cureus 2022;14:e25567.
PubMed
PMC
Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry. Europace 2019;21:1013–22.
PubMed
Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljugic Z, Manola S, et al. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan region: the BALKAN-AF survey. Sci Rep 2016;6:20432.
PubMed
PMC
Juhl Madsen O, Lamberts MK, Fosboel EL, Gislason G, Olesen JB, Strange JE. Trends in percutaneous left atrial appendage occlusion and 1-year mortality: a nationwide cohort study. Eur Heart J 2022;43:ehac544.2137.
Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018;154:1121–201.
PubMed
NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ 2018;27:1209–66.
PubMed
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498.
PubMed
Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol 2020;36:1847–948.
PubMed
Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022;122:20–47.
PubMed
PMC
Saw J, Holmes DR, Cavalcante JL, Freeman JV, Goldsweig AM, Kavinsky CJ, et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. JACC Cardiovasc Interv 2023;16:1384–400.
PubMed
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 2023;149:e1–156.
PubMed
PMC
Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. EuroIntervention 2020;15:1133–80.
PubMed
Tzikas A, Holmes DR Jr, Gafoor S, Ruiz CE, Blomström-Lundqvist C, Diener HC, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace 2017;19:4–15.
PubMed
PMC
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019;74:104–32.
PubMed
Anic A, Bakovic D, Jurisic Z, Farkowski M, Lisica L, Breskovic T, et al. Diagnostic and therapeutic pathways for the malignant left atrial appendage: European Heart Rhythm Association physician survey. Europace 2023;25:euad204.
PubMed
PMC
Camm AJ. Leap or lag: left atrial appendage closure and guidelines. Europace 2023;25:euad067.
PubMed
PMC
Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. Europace 2020;22:184.
PubMed
National Institute for Health and Clinical Excellence . Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance. Heart 2010;97:762–5.
PubMed
Di Biase L, Briceno DF, Trivedi C, Mohanty S, Gianni C, Burkhardt JD, et al. Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. Heart Rhythm 2016;13:1197–202.
PubMed
Lee OH, Kim JS, Pak HN, Hong GR, Shim CY, Uhm JS, et al. Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation. Am J Cardiol 2018;121:1534–9.
PubMed
Korsholm K, Berti S, Iriart X, Saw J, Wang DD, Cochet H, et al. Expert recommendations on cardiac computed tomography for planning transcatheter left atrial appendage occlusion. JACC Cardiovasc Interv 2020;13:277–92.
PubMed
Osmancik P, Herman D, Linkova H, Hozman M, Labos M. A comparison of cardiac computed tomography, transesophageal and intracardiac echocardiography, and fluoroscopy for planning left atrial appendage closure. J Atr Fibrillation 2021;13:20200449.
PubMed
PMC
Sharma PS, Padala SK, Gunda S, Koneru JN, Ellenbogen KA. Vascular complications during catheter ablation of cardiac arrhythmias: a comparison between vascular ultrasound guided access and conventional vascular access. J Cardiovasc Electrophysiol 2016;27:1160–6.
PubMed
Yamagata K, Wichterle D, Roubíček T, Jarkovský P, Sato Y, Kogure T, et al. Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial). Europace 2018;20:1107–14.
PubMed
Sobolev M, Shiloh AL, Di Biase L, Slovut DP. Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. Europace 2017;19:850–5.
PubMed
Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. Cochrane Database Syst Rev 2015;1:CD011447.
PubMed
PMC
Kupó P, Pap R, Sághy L, Tényi D, Bálint A, Debreceni D, et al. Ultrasound guidance for femoral venous access in electrophysiology procedures—systematic review and meta-analysis. J Interv Card Electrophysiol 2020;59:407–14.
PubMed
PMC
Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J 2023;44:3948–4042.
PubMed
Vizzari G, Grasso C, Sardone A, Mazzone P, Laterra G, Frazzetto M, et al. Real-world experience with the new Watchman FLX device: data from two high-volume sicilian centers. The FLX-iEST registry. Catheter Cardiovasc Interv 2022;100:154–60.
PubMed
Price MJ, Friedman DJ, Du C, Wang Y, Lin Z, Curtis JP, et al. Comparative safety of transcatheter LAAO with the first-generation Watchman and next-generation Watchman FLX devices. JACC Cardiovasc Interv 2022;15:2115–23.
PubMed
Paitazoglou C, Meincke F, Bergmann MW, Eitel I, Fink T, Vireca E, et al. The ALSTER-FLX Registry: 3-month outcomes after left atrial appendage occlusion using a next-generation device, a matched-pair analysis to EWOLUTION. Heart Rhythm 2022;19:917–26.
PubMed
Lakkireddy D, Thaler D, Ellis CR, Swarup V, Sondergaard L, Carroll J, et al. Outcomes of the roll-in cohort of the Amulet IDE trial of left atrial appendage occlusion. Heart Rhythm O2 2022;3:493–500.
PubMed
PMC
Chen S, Chun KRJ, Bordignon S, Weise FK, Nagase T, Perrotta L, et al. Left atrial appendage occlusion using LAmbre Amulet and Watchman in atrial fibrillation. J Cardiol 2019;73:299–306.
PubMed
Tilz RR, Fink T, Bartus K, Wong T, Vogler J, Nentwich K, et al. A collective European experience with left atrial appendage suture ligation using the LARIAT+ device. Europace 2020;22:924–31.
PubMed
Betts TR, Grygier M, Nielsen Kudsk JE, Schmitz T, Sandri M, Casu G, et al. Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility post-approval study. Europace 2023;25:914–21.
PubMed
PMC
Bhogal S, Aladin AI, Wermers JP, Morrison N, Gray N, Waksman R. Review of late-breaking trials from CRT 2022. Cardiovasc Revasc Med 2022;40S:3–7.
PubMed
PMC
Merdler I, Reddy PK, Bhogal S, Wermers JP, Salimes BG, Gray N, et al. Review of late-breaking trials from CRT 2023. Cardiovasc Revasc Med 2023;53:S3–9.
PubMed
Lakkireddy D, Thaler D, Ellis CR, Swarup V, Sondergaard L, Carroll J, et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial. Circulation 2021;144:1543–52.
PubMed
PMC
Messele LF, Khan MZ, Darden D, Agarwal S, Krishan S, Pasupula DK, et al. Outcomes of percutaneous left atrial appendage occlusion device implantation in atrial fibrillation patients based on underlying stroke risk. Europace 2023;25:1415–22.
PubMed
PMC
Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534–42.
PubMed
Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation 2013;127:720–9.
PubMed
Bergmann MW, Betts TR, Sievert H, Schmidt B, Pokushalov E, Kische S, et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. EuroIntervention 2017;13:877–84.
PubMed
Berti S, Pastormerlo LE, Rezzaghi M, Trianni G, Paradossi U, Cerone E, et al. Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. Heart 2016;102:1969–73.
PubMed
Korsholm K, Nielsen KM, Jensen JM, Jensen HK, Andersen G, Nielsen-Kudsk JE. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. EuroIntervention 2017;12:2075–82.
PubMed
Landmesser U, Schmidt B, Nielsen-Kudsk JE, Lam SCC, Park JW, Tarantini G et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention 2017;13:867–76.
PubMed
Saw J, Tzikas A, Shakir S, Gafoor S, Omran H, Nielsen-Kudsk JE, et al. Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the amplatzer cardiac plug. JACC Cardiovasc Interv 2017;10:391–9.
PubMed
Kar S, Doshi SK, Sadhu A, Horton R, Osorio J, Ellis C, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation 2021;143:1754–62.
PubMed
Ellis CR, Jackson GG, Kanagasundram AN, Mansour M, Sutton B, Houle VM, et al. Left atrial appendage closure in patients with prohibitive anatomy: insights from PINNACLE FLX. Heart Rhythm 2021;18:1153–61.
PubMed
Korsholm K, Samaras A, Andersen A, Jensen JM, Nielsen-Kudsk JE. The Watchman FLX device: first European experience and feasibility of intracardiac echocardiography to guide implantation. JACC Clin Electrophysiol 2020;6:1633–42.
PubMed
Paitazoglou C, Bergmann MW, Ince H, Kische S, Romanov A, Schmitz T, et al. True efficacy of LAA closure: patient outcomes on long-term single-antiplatelet or no therapy: insights from the EWOLUTION registry. J Invasive Cardiol 2022;34:E348–55.
PubMed
Simard T, Jung RG, Lehenbauer K, Piayda K, Pracoń R, Jackson GG, et al. Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol 2021;78:297–313.
PubMed
Cepas-Guillén P, Flores-Umanzor E, Leduc N, Bajoras V, Perrin N, Farjat-Pasos J, et al. Impact of device implant depth after left atrial appendage occlusion. JACC Cardiovasc Interv 2023;16:2139–49.
PubMed
Saliba WI, Kawai K, Sato Y, Kopesky E, Cheng Q, Ghosh SKB, et al. Enhanced thromboresistance and endothelialization of a novel fluoropolymer-coated left atrial appendage closure device. JACC Clin Electrophysiol 2023;9:1555–67.
PubMed
Lakkireddy D, Nielsen-Kudsk JE, Windecker S, Thaler D, Price MJ, Gambhir A, et al. Mechanisms, predictors, and evolution of severe peri-device leaks with two different left atrial appendage occluders. Europace 2023;25:euad237.
PubMed
PMC
Della Rocca DG, Murtaza G, Di Biase L, Akella K, Krishnan SC, Magnocavallo M, et al. Radiofrequency energy applications targeting significant residual leaks after watchman implantation: a prospective, multicenter experience. JACC Clin Electrophysiol 2021;7:1573–84.
PubMed
Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Della Bella P, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887–9.
PubMed
Gorgis S, Dabbagh MF, Mishra K, Ahluwalia G, Hana A, Fram G, et al. Unprotected discharge: absence of stroke prevention strategies in patients with atrial fibrillation admitted for bleeding. J Interv Card Electrophysiol 2021;62:337–46.
PubMed
Proietti M, Romiti GF, Romanazzi I, Farcomeni A, Staerk L, Nielsen PB, et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2018;261:84–91.
PubMed
Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 2015;110:328–35.
PubMed
Staerk L, Lip GY, Olesen JB, Fosbøl EL, Pallisgaard JL, Bonde AN, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 2015;351:h5876.
PubMed
PMC
Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Balachander N, et al. Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. Therap Adv Gastroenterol 2021;14:1756284821997352.
PubMed
PMC
Ahn HJ, Lee SR, Choi EK, Rhee TM, Kwon S, Oh S, et al. Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: a systematic review and meta-analysis. Br J Clin Pharmacol 2022;88:4676–87.
PubMed
Sanz Segura P, Jimeno Sánchez J, Arbonés-Mainar JM, Sánchez-Rubio Lezcano J, Galache Osuna G, Bernal Monterde V. Percutaneous left atrial appendage closure in patients with gastrointestinal bleeding associated with oral anticoagulants. Scand J Gastroenterol 2023;58:1547–54.
PubMed
Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465–74.
PubMed
PMC
Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113:662–8.
PubMed
Lempereur M, Aminian A, Freixa X, Gafoor S, Shakir S, Omran H, et al. Left atrial appendage occlusion in patients with atrial fibrillation and previous major gastrointestinal bleeding (from the aAmplatzer Cardiac Plug multicenter registry). Am J Cardiol 2017;120:414–20.
PubMed
Gallo F, Ronco F, D’Amico G, Della Rocca DG, Mazzone P, Bordignon S, et al. Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or gastrointestinal bleeding: insights from the LOGIC (left atrial appendage occlusion in patients with gastrointestinal or IntraCranial bleeding) international multicenter registry. Catheter Cardiovasc Interv 2023;101:1144–53.
PubMed
Senzolo M, Garcia-Pagan JC. A major research gap: the use of anticoagulants in cirrhosis. J Hepatol 2023;79:1566–70.
PubMed
Chokesuwattanaskul R, Thongprayoon C, Bathini T, O’Corragain OA, Sharma K, Preechawat S, et al. Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:514–9.
PubMed
Simon TG, Schneeweiss S, Singer DE, Sreedhara SK, Lin KJ. Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation. J Am Heart Assoc 2023;12:e026863.
PubMed
PMC
Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol 2021;75:442–53.
PubMed
Lee SR, Lee HJ, Choi EK, Han KD, Jung JH, Cha MJ, et al. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol 2019;73:3295–308.
PubMed
Mir T, Rawasia WF, Uddin M, Sheikh M, Munir MB, Balla S. Left atrial appendage closure device outcomes among cirrhosis patients with atrial fibrillation: a United States national cohort study. Europace 2023;25:1408–14.
PubMed
PMC
Calvert P, Gupta D. Left atrial appendage occlusion in patients with cirrhotic liver disease: the importance of patient selection. Europace 2023;25:1315–7.
PubMed
PMC
Schreuder F, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, Kerkhoff H, Zock E, et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in The Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol 2021;20:907–16.
PubMed
SoSTART Collaboration . Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol 2021;20:842–53.
PubMed
Population Health Research Institute . NOACs for stroke prevention in patients with atrial fibrillation and previous ICH. 2019. https://classic.clinicaltrials.gov/show/NCT02998905 (8 February 2024, date last assessed).
Liu X, Guo S, Xu Z. Meta-Analysis of oral anticoagulants and adverse outcomes in atrial fibrillation patients after intracranial hemorrhage. Front Cardiovasc Med 2022;9:961000.
PubMed
PMC
Cochrane A, Chen C, Stephen J, Rønning OM, Anderson CS, Hankey GJ, et al. Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database Syst Rev 2023;1:CD012144.
PubMed
PMC
Ivany E, Lane DA, Dan GA, Doehner W, Farkowski MM, Iliodromitis K, et al. Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. Europace 2021;23:806–14.
PubMed
Population Health Research Institute . EdoxabaN foR IntraCranial Hemorrhage survivors with atrial fibrillation (ENRICH-AF). 2019. https://classic.clinicaltrials.gov/show/NCT03950076 (8 February 2024, date last accessed).
Imperial College London Wuerzburg University Hospital Julius-Maximilians University Medical University of Graz University of Liverpool King’s College London, et al. PREvention of STroke in Intracerebral haemorrhaGE survivors with atrial fibrillation. 2019. https://classic.clinicaltrials.gov/show/NCT03996772 (8 February 2024, date last accessed).
University Hospital Lille, Ministry of Health France, Institut National de la Santé Et de la Recherche Médicale France . Avoiding anticoagulation after intracerebral haemorrhage. 2019. https://classic.clinicaltrials.gov/show/NCT03243175 (8 February 2024, date last accsessed).
Oslo University Hospital . Study of antithrombotic treatment after intracerebral haemorrhage. 2018. https://classic.clinicaltrials.gov/show/NCT03186729 (8 February 2024, date last accessed).
Yale University, National Institute of Neurological Disorders and Stroke . Anticoagulation in ICH survivors for stroke prevention and recovery. 2022. https://classic.clinicaltrials.gov/show/NCT03907046 (8 February 2024, date last accessed).
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 2019;140:e125–51.
PubMed
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612–76.
PubMed
National Institute of Cardiology Warsaw Poland, Medical Research Agency Poland . Optimal antiplatelet therapy following left atrial appendage closure in dialyzed patients. 2022. https://classic.clinicaltrials.gov/show/NCT05660811 (8 February 2024, date last accessed).
Garg J, Shah S, Shah K, Bhardwaj R, Contractor T, Mandapati R, et al. Left atrial appendage closure in patients with intracranial hemorrhage. J Interv Card Electrophysiol 2022;64:551–6.
PubMed
Haeusler KG, Tütüncü S, Kunze C, Schurig J, Malsch C, Harder J, et al. Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry. Europace 2019;21:1621–32.
PubMed
Tütüncü S, Olma M, Kunze C, Dietzel J, Schurig J, Fiessler C, et al. Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry. J Neurol 2022;269:470–80.
PubMed
PMC
Polymeris AA, Meinel TR, Oehler H, Hölscher K, Zietz A, Scheitz JF, et al. Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. J Neurol Neurosurg Psychiatry 2022;93:588–98.
PubMed
PMC
Benz AP, Hohnloser SH, Eikelboom JW, Carnicelli AP, Giugliano RP, Granger CB, et al. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. Eur Heart J 2023;44:1807–14.
PubMed
PMC
Paciaroni M, Caso V, Agnelli G, Mosconi MG, Giustozzi M, Seiffge DJ, et al. Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the RENO-EXTEND study. Stroke 2022;53:2620–7.
PubMed
Seiffge DJ, De Marchis GM, Koga M, Paciaroni M, Wilson D, Cappellari M, et al. Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol 2020;87:677–87.
PubMed
PMC
Karl Georg H. Ischaemic stroke in atrial fibrillation patients while on oral anticoagulation-a call for A-C-T-I-O-N. Eur Heart J 2023;44:1815–7.
PubMed
Maarse M, Seiffge D, Fierro N, Tondo C, Pracon R, De Backer O, et al. Left atrial appendage occlusion versus standard of care in patients with atrial fibrillation and a prior thrombo-embolic event despite oral anticoagulant therapy: a propensity score matched comparison. Eur Heart J 2022;43:ehac544.632.
Hamilton Health Sciences Corporation, McMaster University, Population Health Research Institute, Boston Scientific Corporation . The fourth left atrial appendage occlusion study. 2023. https://classic.clinicaltrials.gov/show/NCT05963698 (8 February 2024, date last accessed).
Insel Gruppe AG University Hospital Bern . Early closure of left atrial appendage for patients with atrial fibrillation and ischemic stroke despite anticoagulation therapy. 2024. https://classic.clinicaltrials.gov/show/NCT05976685 (8 February 2024, date last accessed).
Jensen M, Suling A, Metzner A, Schnabel RB, Borof K, Goette A, et al. Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurol 2023;22:45–54.
PubMed
Nippon Medical School, Daiichi Sankyo Co. Ltd . STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation: STABLED study. 2018. https://classic.clinicaltrials.gov/show/NCT03777631 (8 February 2024, date last accessed).
De Potter T, Yodfat O, Shinar G, Neta A, Reddy VY, Neuzil P, et al. Permanent bilateral carotid filters for stroke prevention in atrial fibrillation. Curr Cardiol Rep 2020;22:144.
PubMed
PMC
Javelin Medical, Population Health Research Institute . Carotid implants for PreveNtion of STrokE ReCurrEnce from large vessel occlusion in atrial fibrillation patients treated with oral anticoagulation. 2023. https://classic.clinicaltrials.gov/show/NCT05723926 (8 February 2024, date last accessed).
Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755–9.
PubMed
Stoddard MF, Singh P, Dawn B, Longaker RA. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J 2003;145:676–82.
PubMed
Zhan Y, Joza J, Al Rawahi M, Barbosa RS, Samuel M, Bernier M, et al. Assessment and management of the left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol 2018;34:252–61.
PubMed
Lurie A, Wang J, Hinnegan KJ, McIntyre WF, Belley-Côté EP, Amit G, et al. Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2021;77:2875–86.
PubMed
Steffel J, Heidbüchel H. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment—authors’ reply. Europace 2021;23:1685–6.
PubMed
Kolakowski K, Farkowski MM, Pytkowski M, Gardziejczyk P, Kowalik I, Dąbrowski R, et al. The comparative effectiveness and safety of different anticoagulation strategies for treatment of left atrial appendage thrombus in the setting of chronic anticoagulation for atrial fibrillation or flutter. Cardiovasc Drugs Ther 2023;37:159–68.
PubMed
PMC
Boccuzzi GG, Montabone A, D’Ascenzo F, Colombo F, Ugo F, Muraglia S, et al. Cerebral protection in left atrial appendage closure in the presence of appendage thrombosis. Catheter Cardiovasc Interv 2021;97:511–5.
PubMed
Fink T, Ouyang F, Heeger CH, Sciacca V, Reissmann B, Keelani A, et al. Management of thrombus formation after electrical isolation of the left atrial appendage in patients with atrial fibrillation. Europace 2020;22:1358–66.
PubMed
Popescu SS, Heeger CH, Keelani A, Tilz RR. Percutaneous left atrial appendage closure with the LAmbre device protected by a cerebral protection system in a 76-year-old man with persistent left atrial appendage thrombus. Am J Case Rep 2022;23:e937063.
PubMed
PMC
Mohandes M, Moreno C, Guillén M, Anmad Shihadeh L, Zambrano D. Percutaneous left atrial appendage closure containing thrombus. Cardiol J 2022;29:884–5.
PubMed
PMC
Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol 2017;34:332–95.
PubMed
Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2019;73:A7–8.
PubMed
PMC
Buiten MS, de Bie MK, Rotmans JI, Gabreëls BA, van Dorp W, Wolterbeek R, et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 2014;100:685–90.
PubMed
Vincenti A, Passini E, Fabbrini P, Luise MC, Severi S, Genovesi S. Recurrent intradialytic paroxysmal atrial fibrillation: hypotheses on onset mechanisms based on clinical data and computational analysis. Europace 2014;16:396–404.
PubMed
Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis 2013;62:615–32.
PubMed
Carrero JJ, Trevisan M, Sood MM, Bárány P, Xu H, Evans M, et al. Incident atrial fibrillation and the risk of stroke in adults with chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Clin J Am Soc Nephrol 2018;13:1314–20.
PubMed
PMC
Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008;51:255–62.
PubMed
Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 2016;149:951–9.
PubMed
Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017;6:e004925.
PubMed
PMC
Rebora P, Moia M, Carpenedo M, Valsecchi MG, Genovesi S. Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation. Blood Transfus 2021;19:487–94.
PubMed
PMC
Weijs B, Blaauw Y, Rennenberg RJ, Schurgers LJ, Timmermans CC, Pison L, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011;32:2555–62.
PubMed
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.
PubMed
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
PubMed
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
PubMed
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
PubMed
Kuno T, Takagi H, Ando T, Sugiyama T, Miyashita S, Valentin N, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol 2020;75:273–85.
PubMed
Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis 2021;78:678–89.e1.
PubMed
Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Eur Heart J 2018;39:2314–25.
PubMed
PMC
Genovesi S, Rebora P, Gallieni M, Stella A, Badiali F, Conte F, et al. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. J Nephrol 2017;30:573–81.
PubMed
Kefer J, Tzikas A, Freixa X, Shakir S, Gafoor S, Nielsen-Kudsk JE, et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol 2016;207:335–40.
PubMed
Fink T, Paitazoglou C, Bergmann MW, Sano M, Keelani A, Sciacca V, et al. Left atrial appendage closure in end-stage renal disease and hemodialysis: data from a German multicenter registry. Catheter Cardiovasc Interv 2023;101:610–9.
PubMed
Munir MB, Khan MZ, Darden D, Nishimura M, Vanam S, Pasupula DK, et al. Association of chronic kidney disease and end-stage renal disease with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: insights from the national inpatient sample of 36,065 procedures. Heart Rhythm O2 2021;2:472–9.
PubMed
PMC
Fastner C, Brachmann J, Lewalter T, Zeymer U, Sievert H, Borggrefe M, et al. Left atrial appendage closure in patients with chronic kidney disease: results from the German multicentre LAARGE registry. Clin Res Cardiol 2021;110:12–20.
PubMed
PMC
Luani B, Genz C, Herold J, Mitrasch A, Mitusch J, Wiemer M, et al. Cerebrovascular events, bleeding complications and device related thrombi in atrial fibrillation patients with chronic kidney disease and left atrial appendage closure with the WATCHMAN device. BMC Cardiovasc Disord 2019;19:112.
PubMed
PMC
Al Ali R, Vukadinović D, Maziak W, Katmeh L, Schwarz V, Mahfoud F, et al. Cardiovascular effects of waterpipe smoking: a systematic review and meta-analysis. Rev Cardiovasc Med 2020;21:453–68.
PubMed
Fundación EPIC . Left atrial appendage occlusion with WATCHMAN® device in patients with non-valvular atrial fibrillation and end-stage chronic kidney disease on hemodialysis. 2018. https://classic.clinicaltrials.gov/show/NCT03446794 (8 February 2024, date last accessed).
University of Magdeburg . Left atrial appendage occlusion vs. usual care in patients with atrial fibrillation and severe chronic kidney disease. 2014. https://classic.clinicaltrials.gov/show/NCT02039167 (8 February 2024, date last accessed).
Population Health Research Institute . The Strategy to Prevent Hemorrhage Associated with Anticoagulation in Renal Disease Management (STOP HARM) trial. 2016. https://classic.clinicaltrials.gov/show/NCT02885545 (8 February 2024, date last accessed).
Vallurupalli S, Sharma T, Al’Aref S, Devabhaktuni SR, Dhar G. Left atrial appendage closure: an alternative to anticoagulation for stroke prevention in patients with kidney disease. Kidney360 2022;3:396–402.
PubMed
PMC
Genovesi S, Porcu L, Rebora P, Slaviero G, Casu G, Bertoli S, et al. Long term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study. Clin Kidney J 2023;16:2683–1692.
PubMed
PMC
de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother 2021;7:f30–9.
PubMed
PMC
Kornej J, Henger S, Seewöster T, Teren A, Burkhardt R, Thiele H, et al. Prevalence of atrial fibrillation dependent on coronary artery status: insights from the LIFE-Heart study. Clin Cardiol 2020;43:1616–23.
PubMed
PMC
Camen S, Csengeri D, Geelhoed B, Niiranen T, Gianfagna F, Vishram-Nielsen JK, et al. Risk factors, subsequent disease onset, and prognostic impact of myocardial infarction and atrial fibrillation. J Am Heart Assoc 2022;11:e024299.
PubMed
PMC
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513–24.
PubMed
Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;380:1509–24.
PubMed
Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019;394:1335–43.
PubMed
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423–34.
PubMed
Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019;40:3757–67.
PubMed
Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace 2020;22:33–46.
PubMed
Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation 2020;141:1618–27.
PubMed
Ancedy Y, Lecoq C, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, et al. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: what is the impact of guideline adherence? Int J Cardiol 2016;203:987–94.
PubMed
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–619.
PubMed
Wang Y, Wu D, Ma J, Liu X, Zhang H, So CY, et al. The feasibility and safety of “one-stop” left atrial appendage closure and percutaneous coronary intervention in atrial fibrillation patients with significant coronary artery disease (PCI-LAAC study). Am J Cardiovasc Dis 2021;11:679–87.
PubMed
PMC
Losik D, Romanov A, Grazhdankin I, Shabanov V, Ponomarev D, Mikheenko I, et al. Feasibility of concomitant left atrial appendage closure and percutaneous coronary intervention in patients with acute coronary syndrome and atrial fibrillation: a randomized pilot study. Heart Vessels 2023;38:881–8.
PubMed
Meshalkin Research Institute of Pathology of Circulation, Boston Scientific Corporation . Left atrial appendage closure compared to standard antiplatelet therapy in patients with AF who underwent PCI. 2015. https://classic.clinicaltrials.gov/show/NCT02492230 (8 February 2024, date last accessed).
Yonsei University . Safety and efficacy of left atrial appendage closure versus antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation due to complex coronary artery disease. 2016. https://classic.clinicaltrials.gov/show/NCT02606552 (8 February 2024, date last accessed).
Noseworthy PA, Yao X, Deshmukh AJ, Van Houten H, Sangaralingham LR, Siontis KC, et al. Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation. J Am Heart Assoc 2015;4:e002597.
PubMed
PMC
Wintgens L, Romanov A, Phillips K, Ballesteros G, Swaans M, Folkeringa R, et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. Europace 2018;20:1783–9.
PubMed
Pasupula DK, Siddappa Malleshappa SK, Munir MB, Bhat AG, Anandaraj A, Jakkoju A, et al. Combined atrial fibrillation ablation and left atrial appendage occlusion procedure in the United States: a propensity score matched analysis from 2016–2019 national readmission database. Europace 2023;25:390–9.
PubMed
PMC
Romanov A, Pokushalov E, Artemenko S, Yakubov A, Stenin I, Kretov E, et al. Does left atrial appendage closure improve the success of pulmonary vein isolation? Results of a randomized clinical trial. J Interv Card Electrophysiol 2015;44:9–16.
PubMed
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research, Bayer, Biotronik Canada Inc . Optimal anticoagulation for higher risk patients post-catheter ablation for atrial fibrillation trial. 2016. https://classic.clinicaltrials.gov/show/NCT02168829 (8 February 2024, date last accessed).
Phillips KP, Walker DT, Humphries JA. Combined catheter ablation for atrial fibrillation and Watchman(R) left atrial appendage occlusion procedures: five-year experience. J Arrhythm 2016;32:119–26.
PubMed
PMC
Wilber DJ. PowerPoint presentation (acc.org). 2021. https://www.acc.org/education-and-meetings/image-and-slide-gallery/~/media/B4DF9BAC740A46198403DBE12AB7E193.pdf (8 February 2024, date last accessed).
Nishimura M, Lupercio-Lopez F, Hsu JC. Left atrial appendage electrical isolation as a target in atrial fibrillation. JACC Clin Electrophysiol 2019;5:407–16.
PubMed
Rillig A, Tilz RR, Lin T, Fink T, Heeger CH, Arya A, et al. Unexpectedly high incidence of stroke and left atrial appendage thrombus formation after electrical isolation of the left atrial appendage for the treatment of atrial tachyarrhythmias. Circ Arrhythm Electrophysiol 2016;9:e003461.
PubMed
Panikker S, Jarman JW, Virmani R, Kutys R, Haldar S, Lim E, et al. Left atrial appendage electrical isolation and concomitant device occlusion to treat persistent atrial fibrillation: a first-in-human safety, feasibility, and efficacy study. Circ Arrhythm Electrophysiol 2016;9:e003710.
PubMed
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187–98.
PubMed
Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;371:967–8.
PubMed
Attinger-Toller A, Maisano F, Senn O, Taramasso M, Shakir S, Possner M, et al. “One-Stop shop”: safety of combining transcatheter aortic valve replacement and left atrial appendage occlusion. JACC Cardiovasc Interv 2016;9:1487–95.
PubMed
Drosos I, De Rosa R, Cremer S, Seppelt PC, Hemmann K, Oppermann J, et al. Percutaneous left atrial appendage occlusion in a frail, high-risk, octogenarian patient population, after having undergone transcatheter aortic valve implantation. BMC Cardiovasc Disord 2022;22:349.
PubMed
PMC
D’Amico G, Estevez-Loureiro R, Rofastes XF, Ronco F, Nombela-Franco L, Melica B, et al. Combined procedure of percutaneous mitral valve repair and left atrial appendage occlusion: a multicenter study. JACC Cardiovasc Interv 2021;14:590–2.
PubMed
Kleinecke C, Buffle E, Link J, Häner J, Sedaghat A, Galea R, et al. Amplatzer left atrial appendage closure: single versus combined procedures. Catheter Cardiovasc Interv 2021;97:E973–81.
PubMed
Kuwata S, Taramasso M, Zuber M, Suetsch G, Attinger-Toller A, Wicki D, et al. Feasibility of concomitant MitraClip and left atrial appendage occlusion. EuroIntervention 2017;12:1940–5.
PubMed
Lane CE, Eleid MF, Holmes DR Jr. An under-recognized high-risk atrial fibrillation population: analyzing transcatheter mitral valve repair patients for left atrial appendage closure device application. Catheter Cardiovasc Interv 2019;94:274–9.
PubMed
Arellano-Serrano C, Monivas V, Estevez-Loureiro R. Combined percutaneous treatment of severe triscuspid regurgitation and left atrial appendage closure. J Invasive Cardiol 2019;31:E4–5.
PubMed
Belli M, Zanin F, Macrini M, Barone L, Marchei M, Muscoli S, et al. Combined MitraClip and left atrial appendage occlusion: is it still a Utopia? Front Cardiovasc Med 2022;9:940560.
PubMed
PMC
Kuwata S, Vierecke J, Gloekler S, Maisano F, Meier B, Nietlispach F. Left atrial appendage closure for “primary primary” prevention during percutaneous closure of septal defects in patients with large atria but no atrial fibrillation. Cardiol J 2018;25:179–87.
PubMed
Song Y, Xing H, Koch PD, Li X, Zhang Y. The feasibility and safety of combining atrial septal defect/patent foramen ovale and left atrial appendage closure: a systematic review and meta-analysis. Front Cardiovasc Med 2022;9:1080257.
PubMed
PMC
Tzikas A, Samaras A, Kartas A, Vasdeki D, Fotos G, Dividis G, et al. Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial. Eur Heart J Cardiovasc Pharmacother 2021;7:f63–71.
PubMed
Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016;115:31–9.
PubMed
Ozaki AF, Choi AS, Le QT, Ko DT, Han JK, Park SS, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2020;13:e005969.
PubMed
Chen S, Weise FK, Chun KRJ, Schmidt B. Antithrombotic strategies after interventional left atrial appendage closure: an update. Expert Rev Cardiovasc Ther 2018;16:675–8.
PubMed
Branca L, Tomasoni D, Cimino G, Cersosimo A, Lombardi CM, Chizzola G, et al. Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure. J Cardiovasc Med (Hagerstown) 2023;24:12–9.
PubMed
Active Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–12.
PubMed
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.
PubMed
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the aged study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503.
PubMed
Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020;383:1735–45.
PubMed
Riegler L, Palermi S, Scarafile R, Gioia R, Pastore F, Lombardi A, et al. Clinical and multi-modality imaging approach in the selection of patients for left atrial appendage closure. Rev Cardiovasc Med 2021;22:1197–204.
PubMed
Cruz-González I, Trejo-Velasco B. Percutaneous left atrial appendage occlusion in the current practice. Kardiol Pol 2021;79:255–68.
PubMed
Ledwoch J, Sievert K, Boersma LVA, Bergmann MW, Ince H, Kische S, et al. Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN. Europace 2020;22:1036–43.
PubMed
Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, et al. Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation. J Am Coll Cardiol 2022;79:1785–98.
PubMed
PMC
Freeman J, Hsu JC, Kapadia S, Yeh R, Price M, Nair DG, et al. Ce-452771-4 outcomes with different postprocedural antithrombotic therapy regimens following left atrial appendage occlusion. Heart Rhythm 2023;20:S36–7.
Carvalho PEP, Gewehr DM, Miyawaki IA, Nogueira A, Felix N, Garot P, et al. Comparison of initial antithrombotic regimens after left atrial appendage occlusion: a systematic review and network meta-analysis. J Am Coll Cardiol 2023;82:1765–73.
PubMed
Mhanna M, Beran A, Al-Abdouh A, Jabri A, Al-Aaraj A, Sajdeya O, et al. Single versus dual antiplatelet therapy following left atrial appendage occlusion in patients with high bleeding risk. Curr Probl Cardiol 2022;47:101269.
PubMed
Vignali L, Gurgoglione FL, Barocelli F, Cattabiani MA, Solinas E, Maini A, et al. Looking for optimal antithrombotic strategy after transcatheter left atrial appendage occlusion: a real-world comparison of different antiplatelet regimens. Int J Cardiol 2023;371:92–9.
PubMed
Rodriguez-Gabella T, Nombela-Franco L, Regueiro A, Jiménez-Quevedo P, Champagne J, O’Hara G, et al. Single antiplatelet therapy following left atrial appendage closure in patients with contraindication to anticoagulation. J Am Coll Cardiol 2016;68:1920–1.
PubMed
Azienda Ospedaliero Universitaria Maggiore della Carita, Abbott Medical Devices . Head-to-head comparison of single versus dual antiplatelet treatment strategy after percutaneous left atrial appendage closure: a multicenter, randomized study. 2021. https://classic.clinicaltrials.gov/show/NCT05554822 (8 February 2024, date last accessed).
Cepas-Guillen PL, Flores-Umanzor E, Regueiro A, Brugaletta S, Ibañez C, Sanchis L, et al. Low dose of direct oral anticoagulants after left atrial appendage occlusion. J Cardiovasc Dev Dis 2021;8:142.
PubMed
PMC
Della Rocca DG, Magnocavallo M, Di Biase L, Mohanty S, Trivedi C, Tarantino N, et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc Interv 2021;14:2353–64.
PubMed
Freixa X. Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA). 2019. https://classic.clinicaltrials.gov/show/NCT05632445 (8 February 2024, date last accessed).
Freixa X, Cruz-González I, Cepas-Guillén P, Millan X, Flores-Umanzor E, Asmarats L, et al. A39887XF. Low dose direct oral anticoagulation vs. DAPT after LAAO EuroPCR. 2023. https://eposter.europa-organisation.com/2023/europcr/index/slide/abstract/620 (8 February 2024, date last accessed).
Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Institut universitaire de cardiologie et de pneumologie de Québec University Laval . Short-term anticoagulation versus antiplatelet therapy for preventing device thrombosis following left atrial appendage closure. 2018. https://classic.clinicaltrials.gov/show/NCT03568890 (8 February 2024, date last accessed).
Sondergaard L, Wong YH, Reddy VY, Boersma LVA, Bergmann MW, Doshi S, et al. Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv 2019;12:1055–63.
PubMed
Schmidt B, Nielsen-Kudsk JE, Ellis CR, Thaler D, Sabir SA, Gambhir A, et al. Incidence, predictors, and clinical outcomes of device-related thrombus in the Amulet IDE trial. JACC Clin Electrophysiol 2023;9:96–107.
PubMed
Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN, et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation 2018;138:874–85.
PubMed
Dukkipati SR, Holmes DR Jr, Doshi SK, Kar S, Singh SM, Gibson D, et al. Impact of peridevice leak on 5-year outcomes after left atrial appendage closure. J Am Coll Cardiol 2022;80:469–83.
PubMed
Alkhouli M, Du C, Killu A, Simard T, Noseworthy PA, Friedman PA, et al. Clinical impact of residual leaks following left atrial appendage occlusion: insights from the NCDR LAAO registry. JACC Clin Electrophysiol 2022;8:766–78.
PubMed
PMC
Sharma SP, Turagam MK, Gopinathannair R, Reddy V, Kar S, Mohanty S, et al. Direct current cardioversion of atrial fibrillation in patients with left atrial appendage occlusion devices. J Am Coll Cardiol 2019;74:2267–74.
PubMed
Maarse M, Wintgens LIS, Ponomarenko A, Phillips KP, Romanov AB, Ballesteros G, et al. Impact of anticoagulation strategy after left atrial appendage occlusion in patients requiring direct current cardioversion. J Cardiovasc Electrophysiol 2021;32:737–44.
PubMed